Denmark’s central bank followed its European counterpart with a quarter-point interest-rate cut to defend the krone’s peg to ...

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug Ozempic to include kidney disease risk ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

Who shone in 2024? Check out the countries that overcame global challenges and reached the top of the financial podium ...

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today and set a price target of $155.00.

Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x. Learn more about NVO stock here.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holding ...

Denmarks economic prospects are surging, with the government revising GDP growth forecasts upwards for 2024 and 2025, largely ...